Ernexa Therapeutics Inc. Increase (Decrease) in Due to Related Parties
Ernexa Therapeutics Inc. (ERNA) reported Increase (Decrease) in Due to Related Parties of -$500.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2026-08-06
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for the quarter ending 2026-06-30 was $0.00.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for the quarter ending 2026-03-31 was -$500.00K.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for the quarter ending 2024-12-31 was -$559.00K.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for the quarter ending 2024-09-30 was $228.00K.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for fiscal 2025 was $750.00K.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for fiscal 2024 was -$1.21M.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for fiscal 2023 was -$1.75M, a 159.20% decline from fiscal 2022.
- Ernexa Therapeutics Inc. increase (decrease) in due to related parties for fiscal 2022 was $2.96M.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$500.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$500.00K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $750.00K 10-K · filed 2026-03-13 | |||
| 2024-12-31 | -$559.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$331.00K derived: sum of 2 quarters · filed 2026-03-13 | -$768.00K derived: sum of 3 quarters · filed 2026-03-13 | -$1.21M 10-K · filed 2026-03-13 |
| 2024-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$209.00K derived: sum of 2 quarters · filed 2025-11-07 | -$646.00K 10-Q · filed 2025-11-07 | -$1.08M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$437.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$874.00K 10-Q · filed 2025-08-13 | -$1.31M derived: sum of 3 quarters · filed 2025-08-13 | -$1.75M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$437.00K 10-Q · filed 2025-05-07 | -$874.00K derived: sum of 2 quarters · filed 2025-05-07 | -$1.31M derived: sum of 3 quarters · filed 2025-05-07 | -$1.75M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$875.00K derived: sum of 2 quarters · filed 2025-03-12 | -$1.31M derived: sum of 3 quarters · filed 2025-03-12 | -$1.75M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$438.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$875.00K derived: sum of 2 quarters · filed 2024-11-12 | -$1.31M 10-Q · filed 2024-11-12 | -$1.75M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$437.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$875.00K 10-Q · filed 2024-08-13 | -$1.31M derived: sum of 3 quarters · filed 2024-08-13 | $2.08M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$438.00K 10-Q · filed 2024-05-14 | -$875.00K derived: sum of 2 quarters · filed 2024-05-14 | $2.52M derived: sum of 3 quarters · filed 2024-05-14 | $2.52M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.96M derived: sum of 2 quarters · filed 2024-03-14 | $2.96M derived: sum of 3 quarters · filed 2024-03-14 | $2.96M 10-K · filed 2024-03-14 |
| 2022-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.39M derived: sum of 2 quarters · filed 2023-11-13 | $3.39M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |